Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Series C round brings $58mm to LAM Therapeutics

Executive Summary

LAM Therapeutics Inc. (genomics-based drug development) raised $58mm from undisclosed investors in its Series C round. The company's lead candidates (all in or through Phase I trials) include blood cancer therapy LAM003, B-cell lymphoma project LAM002, and mTOR inhibitor LAM001 for the rare lung disease lymphangioleiomyomatosis.
Deal Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies

Advertisement
UsernamePublicRestriction

Register